Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)

Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)

Abstract Background Management guidelines for obesity suggest maintaining a minimum of 5% body weight reduction to help prevent or lower the risk of developing conditions such as hypertension and type 2 diabetes. However, achieving long‐term weight control is difficult with lifestyle modification al...

Full description

Bibliographic Details
Main Authors: Aleksandrina Ruseva, Wojciech Michalak, Zhenxiang Zhao, Anthony Fabricatore, Bríain Ó. Hartaigh, Devika Umashanker
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Obesity Science & Practice
Subjects:
anti‐obesity agents
body mass index
evidence‐based practice
obesity
weight loss
Online Access:https://doi.org/10.1002/osp4.737

Internet

https://doi.org/10.1002/osp4.737

Similar Items